NCT07581496Recruiting
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality. Current risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality. Primary objective is to investigate the detectability of ct-DNA in T1G3 urothelial bladder cancer patients and build a biobank through collection of different sample types (urine, plasma) in T1G3 bladder cancer patients which allows future retrospective testing.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 35 (estimated)
- First submitted
- 5 May 2026
- Start date
- 18 Jun 2025
- Primary completion date
- 1 Jun 2030
- Lead sponsor
- University Hospital, Basel, Switzerland
- Diseases
- Bladder cancer
- NCT number
- NCT07581496
What you commit to
- Study type: Observational
- Planned participants: 35
- From 18 Jun 2025 to the primary completion date, 1 Jun 2030
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with metastases or concomitant upper tract tumor at diagnosis will
Other illness
- Patients with non T1 G3 cancers
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
Age
- Vulnerable persons (e.g. \< 18y of age, unable to consent to the study)
Other
- Patients with upstaging, either at re-TUR-B or after immediate radical cystectomy
Who the study is looking for
- patients \> 18 years of age, able to give informed consent as documented by signature,
- patients with a cystoscopically proven bladder cancer, suspicious for T1 stage, who will undergo TUR-B
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitätsspital Basel Coordinator of this site? Confirm its status | Basel | Switzerland | Recruiting |
| Luzerner Kantonsspital Coordinator of this site? Confirm its status | Lucerne | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.